Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Update

Alterity Therapeutics Limited (NASDAQ:ATHE) saw a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 553,500 shares, an increase of 556.6% from the January 15th total of 84,300 shares. Approximately 6.4% of the company’s shares are sold short. Based on an average daily volume of 448,900 shares, the short-interest ratio is presently 1.2 days.

Alterity Therapeutics Stock Down 3.2 %

NASDAQ ATHE opened at $4.20 on Thursday. The firm’s fifty day moving average price is $3.27 and its two-hundred day moving average price is $1.98. Alterity Therapeutics has a 1 year low of $1.00 and a 1 year high of $5.87.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Alterity Therapeutics stock. HB Wealth Management LLC raised its stake in Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,883 shares of the company’s stock after purchasing an additional 8,100 shares during the period. HB Wealth Management LLC owned 0.44% of Alterity Therapeutics worth $110,000 at the end of the most recent quarter. Institutional investors own 2.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Maxim Group lifted their price objective on Alterity Therapeutics from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, January 30th. Benchmark lowered Alterity Therapeutics from a “speculative buy” rating to a “hold” rating in a report on Monday, February 3rd.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.